TALEN

TALEN1-ryr1a

ID

ZDB-TALEN-131028-4

Name

TALEN1-ryr1a

Previous Names

ryr1a-ex6 TALEN (1)

Target

ryr1a (1)

Target Sequence 1

5' - GGACCATTCACCCTGCAT - 3'

Target Sequence 2

5' - CTGACCTTCTCACCCT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
z42	ryr1a

Expression

Gene expression in Wild Types + TALEN1-ryr1a

No data available

Phenotype

Phenotype resulting from TALEN1-ryr1a

No data available

Phenotype of all Fish created by or utilizing TALEN1-ryr1a

Phenotype	Fish	Conditions	Figures
somite ryr1a expression decreased amount, abnormal	ryr1a^z42/z42	standard conditions	Fig. S5 from Chagovetz et al., 2019
somite ryr1a expression decreased amount, abnormal	ryr1a^z42/z42	standard conditions	Fig. S2 from Chagovetz et al., 2019
muscle pioneer decreased amount, abnormal	ryr1a^z42/z42	standard conditions	Fig. 2. from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal	ryr1a^z42/z42	standard conditions	Fig. 2. from Chagovetz et al., 2019
fast muscle cell decreased amount, abnormal	ryr1a^z42/z42	standard conditions	Fig. 2. from Chagovetz et al., 2019
whole organism dead, abnormal	ryr1a^z42/z42; ryr1b^mi340/mi340	standard conditions	Figure 3-figure supplement 1 from Volpatti et al., 2020
whole organism viability, abnormal	ryr1a^z42/z42; ryr1b^mi340/mi340	standard conditions	Figure 3-figure supplement 1 from Volpatti et al., 2020
whole organism paralysed, abnormal	ryr1a^z42/z42; ryr1b^mi340/mi340	control	Figure 3-figure supplement 1 from Volpatti et al., 2020
whole organism paralysed, abnormal	ryr1a^z42/z42; ryr1b^z43/z43	standard conditions	Fig. 3 from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal	ryr1a^z42/z42; ryr3^z45/z45	standard conditions	Fig. 2. from Chagovetz et al., 2019
fast muscle cell decreased amount, abnormal	ryr1a^z42/z42; ryr3^z45/z45	standard conditions	Fig. 2. from Chagovetz et al., 2019
ventral mandibular arch increased width, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 6. from Chagovetz et al., 2019
slow muscle cell undulate, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 5. from Chagovetz et al., 2019
swimming decreased occurrence, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 5. from Chagovetz et al., 2019
ventral mandibular arch decreased length, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 6. from Chagovetz et al., 2019
slow muscle cell morphology, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 5. from Chagovetz et al., 2019
Meckel's cartilage morphology, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 6. from Chagovetz et al., 2019
neural tube ventral region nkx6.1 expression decreased amount, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	control	Fig. 2 from Klatt Shaw et al., 2018
slow muscle cell ab1-ryr labeling absent, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 1. from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	control	Fig. 1 from Klatt Shaw et al., 2018
floor plate nkx2.2a expression decreased amount, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	control	Fig. 2 from Klatt Shaw et al., 2018
slow muscle cell muscle pioneer decreased amount, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	control	Fig. 1 from Klatt Shaw et al., 2018
fast muscle cell decreased amount, exacerbated	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	chemical treatment by environment: azumolene sodium	Fig. 1 from Klatt Shaw et al., 2018
slow muscle cell muscle pioneer decreased amount, exacerbated	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	chemical treatment by environment: azumolene sodium	Fig. 1 from Klatt Shaw et al., 2018
fast muscle cell decreased amount, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	control	Fig. 1 from Klatt Shaw et al., 2018
slow muscle cell sarcomere increased size, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 5. from Chagovetz et al., 2019
palatoquadrate arch decreased length, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 6. from Chagovetz et al., 2019
fast muscle cell ab1-ryr labeling absent, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 1. from Chagovetz et al., 2019
slow muscle cell decreased amount, exacerbated	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	chemical treatment by environment: azumolene sodium	Fig. 1 from Klatt Shaw et al., 2018
palatoquadrate arch increased width, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 6. from Chagovetz et al., 2019
somite slow muscle cell increased length, abnormal	ryr1a^z42/z42; ryr1b^z43/z43; ryr3^z45/z45	standard conditions	Fig. 5. from Chagovetz et al., 2019
skeletal muscle cell ptch2 expression decreased distribution, abnormal	ryr1a^z42/z42; ryr2a^z44/z44; ryr3^z45/z45	control	Fig. 3 from Klatt Shaw et al., 2018
skeletal muscle cell ptch2 expression decreased amount, abnormal	ryr1a^z42/z42; ryr2a^z44/z44; ryr3^z45/z45	control	Fig. 3 from Klatt Shaw et al., 2018
neural tube ventral region ptch2 expression decreased amount, abnormal	ryr1a^z42/z42; ryr2a^z44/z44; ryr3^z45/z45	control	Fig. 3 from Klatt Shaw et al., 2018
neural tube ventral region ptch2 expression decreased distribution, abnormal	ryr1a^z42/z42; ryr2a^z44/z44; ryr3^z45/z45	control	Fig. 3 from Klatt Shaw et al., 2018

Citations